PABRON ACE PRO TABLETS

Cold Remedies

◆PABRON ACE PRO TABLETS is a compound of 7 active ingredients such as ibuprofen, L-carbocisteine, and ambroxol hydrochloride, and relieves 11 symptoms associated with the common cold, such as sore throat, cough, runny nose, and fever.

Indication

Relief of various symptoms of a common cold: running nose, stuffy nose, sneezing, sore throat, cough, phlegm (sputum), chills (feeling cold due to fever), fever,headache, joint pain, and muscle pain.

Dosage and administration

Take the following dose with cold or lukewarm water within 30 minutes after a meal whenever possible.

15 years or over: 3 tablets per dose, 3 times daily

Under 15 years: Do not take

Comply with the prescribed dosage and administration instructions.

How to take out the tablets

- ·As shown in the figure, press the convex part of the PTP sheet containing the tablet firmly with your fingertips, break the aluminum foil on the back side, and take out the tablets.
- (If the tablets are inadvertently taken together with the PTP sheet containing them, it will lead to unexpected accidents, such as the sharp edge sticking into the esophageal mucosa.)

ingredient and amount

In 3 tablets

Ibuprofen 200mg

L-carbocysteine 250mg

Ambroxol hydrochloride 15mg

Dihydrocodeine Phosphate 8mg

dl-Methylephedrine Hydrochloride 20mg

Chlorpheniramine Maleate 2.5mg

Riboflavin 4mg

Excipients

cellulose, anhydrous silicic acid , Lactose , Hypromellose, Hydroxypropylcellulose, Sodium starch glycolate, Talc

Precautions relating to ingredient and amount

No need to worry if you have yellow urine after taking the drug because it is caused by the vitamin B2 contained in the drug.

Precautions

When not to use the product

(If you do not follow these instructions, the current symptoms may worsen or adverse reactions/incidents are more likely to occur.)

This product should not be used in the following persons:

Persons who have had an allergic symptom to this drug or its ingredients.

Patients who have experienced asthma from taking this drug or other cold remedies, antipyretic analgesics.

Children under 15 years old

Pregnant women who are expected to give birth within 12 weeks.

Persons undergoing treatment or medication for the following diseases at a medical institution.

Gastric/duodenal ulcer

Blood disease

Liver disease

kidney disease

heart disease

Hypertension

Persons on zidovudine (e.g., Retrovir)

This drug should not be taken together with the following drugs:

Other cold medicines, antipyretics/analgesics, sedatives, expectorants, internal medicine, etc. containing antihistamines (internal medicine for rhinitis, medicine for motion sickness, medicine for allergies, etc.) and gastrointestinal analgesics

• After taking this drug, do not drive a car or operate machinery (sleepiness may occur).

For those who are lactating, do not use this medicine or avoid lactating while using this medicine.

Excretion in milk has been reported in animal tests.

Do not drink alcohol before and after taking this drug.

• Do not take this medicine for more than 5 days

11-Jul-2019 1/2 page

Consultation

• The following persons should contact a physician, pharmacist, or registered salesperson for a consultation before administration.

Patients undergoing medical treatment from a physician or dentist.

Pregnant women or women suspected of being pregnant.

The elderly

Patients who have experienced allergic symptoms associated with drugs, etc.

Persons with the following symptoms:

hyperthermia

urination difficulty

Persons diagnosed with the following diseases or have a history of the following diseases.

Gastric/duodenal ulcer

Blood disease

Liver disease

kidney disease

heart disease

Hypertension

Bronchial asthma

Mixed connective tissue disease

Systemic lupus erythematosus

Ulcerative colitis

Crohn's disease

thyroid disease

Diabetes

Glaucoma

Respiratory functional disorder, obstructive sleep apnea syndrome, adiposity

Skin: rash/redness, itching, edema, and bruises

• If the following symptoms are observed after taking this drug, these may be adverse reactions, so immediately discontinue the use of this drug, and show this document to your physician, pharmacist, or registered salesperson for a consultation.

Gastrointestinal system: nausea/vomiting, loss of appetite, gastric discomfort, stomach pain, stomatitis, heartburn, heaviness in the stomach, gastrointestinal bleeding, abdominal pain, diarrhea, and bloody stool

Feeling of stomach/abdominal distention

Neuropsychiatric system: dizziness, numbness, insomnia, and feeling depressed

Cardiovascular system: palpitations

Respiratory system:

shortness of breath

Urinary system:

urination difficulty

Other: blurred vision, tinnitus, oedema, nosebleeds, bleeding from the gums, defects in hemostasis, bleeding, back pain, excessive drop of body temperature, and general malaise

The following serious symptoms may occur in rare cases. In such cases, immediately seek medical aid from a physician.

Shock (anaphylaxis): Symptoms, such as itching of skin, urticaria, hoarseness, sneezing, itchy throat, breath...

Precautions for storage and handling

Avoid direct sunlight, and store the product in a cool place with little humidity.

Store the product beyond the reach of children.

Do not transfer the drug to other containers. (It may lead to misuse or quality deterioration)

Do not use the product past the expiration date. Even before the expiration date, use the product within 6 months after it is opened (to assure the quality).

(Disclaimer on Multilingual OTC Product Information)

- •This product is a pharmaceutical product approved under a Japanese law, the Law for Ensuring the Quality, Efficacy and Safety of Drugs and Medical Devices, with a view to its sale and use in Japan.
- •Multilingual product information is a translation of the product labeling written in Japanese and provided for your information only. It does not warrant that its contents and the product itself conforms to laws and regulations in countries other than Japan.
- •Multilingual product information is a tentative translation by the provider (or Our Company), and may be modified or altered without notice.
- •The provider (or Our Company) assumes no responsibility for any occurred problem attributable to the contents of the multilingual product information.

11-Jul-2019 2/2 page

21